Abstract library

12 results for "Faron".
#58 Surgical approaches in 84 patients with insulinomas in multiple endocrine neoplasia type 1 (MEN 1)
Introduction: Management of insulinomas in the setting of Multiple Endocrine Neoplasia type 1 (MEN1) remains controversial.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Delphine Vezzosi
#81 Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): our experience in a multidisciplinary team in a university hospital
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have a low incidence and prevalence representing < 2% of all gastrointestinal tumors with a heterogeneous biological behavior and an often complex management.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Jose Manuel Cabezas-Agricola
#100 Mammalian target of rapamycin (mTOR) expression analysis and therapeutic approach in lung and gastroenteropancreatic poorly differentiated endocrine carcinoma (PDEC)
Introduction: PDEC clinically include gastroenteropancreatic PDEC, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). These tumors are clinically similar and aggressive and they are usually treated with platinum compounds. mTOR signalling pathway has emerged as a promising target for well-differentiated endocrine carcinoma therapy. Because of varying behavior, PDEC are usually excluded from clinical trials employing the mTOR inhibitor RAD001.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Emilio Bajetta
#216 Patients Treated for Well-Differentiated Neuroendocrine Tumors: A Study to Evaluate the Ratio of Patients Lost to Follow-up
Introduction: Well-differentiated neuroendocrine tumors (wdNET) are considered more indolent than other epithelial malignancies. Median survival for patients with G1/G2 NET can range from 33 to 223 months.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Rosine Guimbaud
#542 Establishment of a Multidisciplinary Tumor Board for Patients with Neuroendocrine Neoplasms
Introduction: Neuroendocrine neoplasms are rare and multiform, requiring a multidisciplinary approach. We report the experience of a neuroendocrine tumor board (TB) established at our University Hospital.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#764 The Experience of a Multidisciplinary Tumor Board for Patients with Neuroendocrine Neoplasms
Introduction: Neuroendocrine neoplasms are rare and multiform, requiring a multidisciplinary approach. We report the experience of a Neuroendocrine Tumor Board established at our University Hospital.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Laura De Marinis
#765 Everolimus Treatment in a Series of Patients with Advanced Neuroendocrine Tumors
Introduction: Everolimus is an oral mTOR inhibitor that exerts antineoplastic effects inhibiting cell proliferation, survival and angiogenesis. Its activity in advanced neuroendocrine tumors (NETs) has been demonstrated in controlled trials and everolimus was approved by the FDA for the treatment of progressive, advanced pNETs in May 2011.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: Laura De Marinis
Keywords: everolimus, prrt
#1053 Pancreatic Neuroendocrine Tumor and Ileal Carcinoid in Acromegaly. Pluriglandular Association in Non-MEN 1 Patient: A Case Report.
Introduction: Pluriglandolar endocrine disease in patients without familial inherited disease (non-MEN 1) are very rare. Primary Pancreatic Neuroendocrine Tumors (pNET) and ileal carcinoid tumors have different embryologic origin (foregut and midgut respectively).
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Doctor Valbona Lico
#1555 Antitumor Activity of Desmopressin (dDAVP) and the New Analog [V4Q5]dDAVP in Human Small Cell Lung Cancer
Introduction: Lung cancer is the main cause of cancer death. Non small cell lung cancer (NSCLC) cause about 85% of cases and small cell lung cancer (SCLC) represents 15%. Therapy resistance is commonly related with a transformation from adenocarcinoma to SCLC. SCLC shows neuroendocrine (NE) features and exhibits aggressive behavior. In vitro production of vasopressin (AVP) was reported in SCLC. The AVP V1 receptors are associated with mitogenic signaling pathways, while AVP V2 receptor (V2r) is related with an opposite effect. DDAVP is a synthetic analog of AVP that acts as a selective agonist for V2r. DDAVP displays cytostatic and antimetastatic properties in breast and colorectal cancer. In our laboratory a new analog, [V4Q5]dDAVP, showed improved cytostatic activity
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Student PhD Marina Pifano
Authors: Pifano M, Garona J, Alonso D, Ripoll G, ...
Keywords: v2r, antitumor, NE
#1832 Are Cystic Pancreatic Neuroendocrine Tumors an Indolent Entity? Results for a Single Institutional Surgical Series
Introduction: Cystic pancreatic neuroendocrine tumors (CPanNET) are an uncommon variant of pancreatic neuroendocrine tumors (PanNETs). Due to their rarity, there is a lack of knowledge with regards to clinical features and prognosis.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: MD Marco Miotto
Keywords: cystic